Table 4.
Tumor locations accounting for 90% (*) of pharmaceutical antineoplastic expenditure in 2019.
| Tumor Location | % Total Expenditure |
% Total Patients |
Accumulated Expenditure (Pareto) |
|---|---|---|---|
| Breast * | 34.64 | 26.32 | 34.64 |
| Lung cancer non-small cell * | 12.43 | 11.41 | 47.07 |
| Melanoma * | 9.74 | 2.02 | 56.81 |
| Colon * | 8.00 | 11.23 | 64.81 |
| Prostate * | 6.50 | 3.54 | 71.31 |
| Kidney * | 4.70 | 1.70 | 76.01 |
| Ovary * | 4.46 | 5.88 | 80.47 |
| Neuroendocrine * | 3.47 | 1.84 | 83.94 |
| Oral cavity and oropharynx * | 2.94 | 4.04 | 86.88 |
| Soft-tissue sarcoma * | 2.17 | 2.13 | 89.05 |
| Thyroid * | 1.83 | 0.87 | 90.88 |
| Rectum | 1.44 | 4.22 | 92.33 |
| Pancreas exocrine | 1.35 | 4.19 | 93.67 |
| Stomach | 1.22 | 3.00 | 94.90 |
| Brain | 1.22 | 3.86 | 96.11 |
| Uterine cervix | 0.80 | 1.55 | 96.91 |
| Gastrointestinal stromal tumors (GIST) | 0.80 | 1.37 | 97.71 |
| Larynx/hypopharynx | 0.39 | 0.43 | 98.10 |
| Other | 0.35 | 0.00 | 98.44 |
| Urinary bladder | 0.32 | 1.88 | 98.77 |
| Basal cell skin cancer | 0.24 | 0.07 | 99.01 |
| Other cutaneous tumors | 0.16 | 0.18 | 99.17 |
| Unknown primary tumor | 0.15 | 0.14 | 99.33 |
| Hepatic carcinoma | 0.14 | 0.14 | 99.47 |
| Extrahepatic bile duct | 0.12 | 2.24 | 99.59 |
| Anal | 0.11 | 0.32 | 99.70 |
| Endometrium | 0.10 | 1.12 | 99.80 |
| Lung cancer small cell | 0.06 | 3.00 | 99.86 |
| Ewing sarcoma | 0.04 | 0.07 | 99.90 |
| Testicular germinal | 0.03 | 0.25 | 99.93 |
| Esophagus | 0.02 | 1.16 | 99.95 |
| Rhinopharynx/cavum | 0.02 | 0.40 | 99.97 |
| Kaposi sarcoma | 0.01 | 0.04 | 99.98 |
| Thymoma | 0.01 | 0.11 | 99.99 |
| Osteosarcoma | 0.00 | 0.18 | 99.99 |
| Mesothelioma | 0.00 | 0.14 | 99.99 |
| Pancreas endocrine | 0.00 | 0.07 | 99.99 |
| Gallbladder | 0.00 | 0.11 | 100.00 |
| Penis | 0.00 | 0.07 | 100.00 |
| Adrenal | 0.00 | 0.04 | 100.00 |
| Squamous cell skin cancer | 0.00 | 0.04 | 100.00 |